Reports

Ideas That Generate Results

List of Figures

Figure 3-1: Global - Biologics Market (Billion US$), 2013-2018
Figure 3-2: Global - Biologics Market by Segment (%), 2013
Figure 5-1: Global - Biosimilars Market (Million US$), 2013 & 2018
Figure 5-2: Global - Biosimilars Market by Key Segment (%), 2013
Figure 5-3: Global - Biosimilars Market by Key Segment (%), 2018
Figure 5-4: Global - Erythropoietin Biosimilars Market (Million US$), 2013 & 2018
Figure 5-5: Global - HGH Biosimilars Market (Million US$), 2013 & 2018
Figure 5-6: Global - G-CSF Biosimilars Market (Million US$), 2013 & 2018
Figure 5-7: Global - mAb Biosimilars Market (Million US$), 2013 & 2018
Figure 5-8: Global - Insulin Biosimilars Market (Million US$), 2013 & 2018
Figure 5-9: Global - Interferon Biosimilars Market (Million US$), 2013 & 2018

List of Tables

Table 5-1: Global Biosimilar Market - Key Players by Rank
Table 5-2: Global - Biosimilar EPOs Approved for Marketing
Table 5-3: Global Biosimilar EPO Market - Key Players by Rank
Table 5-4: Global - Biosimilar EPOs in Pipeline
Table 5-5: Global - Patent Expiry Status of EPOs
Table 5-6: Global - Biosimilar HGH Approved for Marketing
Table 5-7: Global Biosimilar HGH Market - Key Players by Rank
Table 5-8: Global - Biosimilar HGH in Pipeline
Table 5-9: Global - Biosimilar G-CSF Approved for Marketing
Table 5-10: Global Biosimilar G-CSF Market - Key Players by Rank
Table 5-11: Global - Biosimilar G-CSF in Pipeline
Table 5-12: Global - Patent Expiry Status of G-CSF
Table 5-13: Global - Biosimilar mAbs Approved for Marketing
Table 5-14: Global Biosimilar mAb Market - Key Players by Rank
Table 5-15: Global - Biosimilar mAbs in Pipeline
Table 5-16: Global - Patent Expiry Status of mAbs
Table 5-17: Global - Biosimilar Insulin Approved for Marketing
Table 5-18: Global Biosimilar Insulin Market - Key Players by Rank
Table 5-19: Global - Biosimilar Insulin in Pipeline
Table 5-20: Global - Patent Expiry Status of Insulin
Table 5-21: Global - Biosimilar Interferons Approved for Marketing
Table 5-22: Global - Biosimilar Interferons in Pipeline
Table 5-23: Global - Patent Expiry Status of Interferons
Table 6-1: Biosimilars of US-based Companies Approved for Marketing
Table 6-2: Biosimilars of US-based Companies in Pipeline
Table 6-3: US - Patent Expiry Status of Biologics
Table 6-4: Biosimilars of European Companies Approved for Marketing
Table 6-5: Biosimilars of European Companies in Pipeline
Table 6-6: Europe - Patent Expiry Status of Biologics
Table 6-7: Biosimilars of Indian Companies Approved for Marketing
Table 6-8: Biosimilars of Indian Companies in Pipeline
Table 6-9: Biosimilars of Chinese Companies Approved for Marketing
Table 6-10: Biosimilars of Chinese Companies in Pipeline
Table 6-11: Biosimilars of Korean Companies Approved for Marketing
Table 6-12: Biosimilars of Korean Companies in Pipeline
Table 6-13: Korea - Patent Expiry Status of Biologics